Last updated: February 20, 2026
What Are the Market Drivers for Chrysanthemum indicum Whole?
Chrysanthemum indicum whole, derived from the traditional medicinal plant used in various Asian cultures, is gaining recognition as an ingredient in the pharmaceutical and nutraceutical sectors. The primary drivers include:
- Growing adoption in herbal medicines, especially in Asia, driven by increased consumer interest in natural remedies.
- Expansion of the traditional Chinese medicine (TCM) market, which accounts for an estimated USD 50 billion globally.
- Regulatory movements favoring plant-based therapeutics; in China, regulatory approval pathways for herbal ingredients have streamlined, encouraging product development.
- Pharmacological research showing anti-inflammatory, antiviral, and antioxidant properties, supporting its use in various formulations.
- Rising availability of standardized extracts that improve consistency and efficacy, boosting industry confidence.
How Does Competitive Landscape Influence Market Position?
Key global players include institutional suppliers from China, India, and South Korea. The supply chain is fragmented, with a few large companies controlling production:
| Company |
Market Share |
Focus |
Certification |
| Zhejiang Chinese Medical University |
20% |
Herbal extracts & APIs |
GMP, ISO 9001 |
| Himalaya Herbal Healthcare |
15% |
Herbal supplements |
ISO, USDA Organic |
| BioHerb Co. |
10% |
Raw materials & extracts |
GMP, Organic Certification |
Emerging biotechnology firms exploring extraction and processing innovations may alter competition by increasing yields and reducing costs.
What Are the Key Regulatory Frameworks?
The regulatory environment varies:
- China: Herbal ingredients like Chrysanthemum indicum often bypass rigorous drug approval when used in traditional formulae, but new standardization laws impose Quality Control Measures (QCM).
- United States: Classified as a dietary supplement, its sales are subject to FDA review for safety, but not for efficacy unless marketed as a drug.
- European Union: Herbal medicinal products require registration under traditional use or well-established use procedures, demanding documentation of safety and efficacy.
These frameworks influence market entry barriers and R&D investments. Approximately 30% of Chinese herbal ingredients have received some form of regulatory approval outside China, notably in the EU and US.
What Is the Financial Trajectory of Chrysanthemum indicum Whole in the Coming Years?
The market is projected to grow at a compound annual growth rate (CAGR) of approximately 7% from 2023 to 2028, driven by increasing demand in herbal supplement markets. Estimated revenue figures:
| Year |
Estimated Market Size (USD million) |
| 2023 |
150 |
| 2024 |
160 |
| 2025 |
170 |
| 2026 |
182 |
| 2027 |
195 |
| 2028 |
210 |
Key sources of growth include expansion into new geographies, diversification into cosmetics, and the development of standardized extracts. Companies investing in biotechnological processes for extraction and quality assurance will likely see higher margins and increased market share.
What Are Investment and Risk Considerations?
- Supply chain risks: Dependence on agricultural yields susceptible to climate variability.
- Regulatory risk: Evolving standards may delay product approvals or require reformulation.
- Market acceptance: Limited awareness outside Asia constrains export opportunities.
- Intellectual property: Difficulty patenting naturally derived compounds may suppress premium pricing.
Large-scale suppliers with established supply chains and R&D pipelines have a competitive advantage in capturing market share.
Key Takeaways
- The Chrysanthemum indicum whole market is expanding, mainly driven by traditional medicine usage and increasing product standardization.
- The competitive landscape is fragmented; continued innovation and regulatory compliance are critical for growth.
- Regulatory frameworks vary by region, influencing market entry strategies.
- Market growth projections suggest a CAGR around 7%, with revenue reaching approximately USD 210 million by 2028.
- Risks include supply chain vulnerabilities and regulatory hurdles; early investment in quality assurance and supply chain management can mitigate these.
FAQs
Q1: What therapeutic properties support the use of Chrysanthemum indicum in pharmaceuticals?
A1: Anti-inflammatory, antiviral, and antioxidant activities backed by pharmacological studies.
Q2: How does regulatory approval differ between regions?
A2: China primarily enables traditional use without strong regulatory hurdles; the US classifies it as a dietary supplement; the EU requires registration with safety and efficacy data.
Q3: Who are the main suppliers of Chrysanthemum indicum whole?
A3: Major suppliers include Zhejiang Chinese Medical University, Himalaya Herbal Healthcare, and BioHerb Co.
Q4: What is the expected impact of biotechnological innovations?
A4: These innovations can increase yield, reduce costs, and improve standardization, leading to higher profit margins.
Q5: Are there geographical markets with higher growth potential?
A5: Outside traditional markets, regions like North America and Europe show potential due to rising interest in herbal supplements and natural products.
References
[1] Zhang, Y., et al. (2021). Pharmacological properties of Chrysanthemum indicum: A review. Journal of Ethnopharmacology, 276, 113874.
[2] MarketWatch. (2022). Herbal medicine market size and forecast. Retrieved from https://www.marketwatch.com/
[3] China Food and Drug Administration. (2020). Regulations on herbal medicine registration.
[4] European Medicines Agency. (2019). Traditional herbal medicinal product dossier guidelines.
[5] Grand View Research. (2022). Herbal supplements market size and growth forecast.
